Identification of a novel preclinical candidate for CDK7 inhibition

An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity

Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway

Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin

In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4

Oral Immune Checkpoint Antagonists Dually Targeting TIGIT and PD-1 pathways for Cancer Therapy

Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin

Potent anti-tumor activity correlated with inhibition of DNA damage response genes with highly selective and orally bioavailable CDK12 covalent inhibitors

Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)

Preclinical In vivo evaluation of efficacy, pharmacokinetics and pharmacodynamics of novel PRMT5 inhibitors in multiple tumor models (PRMT5i)